catalog number :
MBS5400388
products full name :
DWORF Antibody
products short name :
[DWORF]
products name syn :
[Affinity Purified Sarcoplasmic/endoplasmic reticulum calcium ATPase regulator DWORF Antibody; Dwarf open reading frame antibody; DWORF antibody; Sarcoplasmic/endoplasmic reticulum calcium ATPase regulator; DWORFSERCA regulator DWORF antibody]
other names :
[Sarcoplasmic/endoplasmic reticulum calcium ATPase regulator DWORF; Sarcoplasmic/endoplasmic reticulum calcium ATPase regulator DWORF; Dwarf open reading frame]
products gene name :
[DWORF]
other gene names :
[DWORF; DWORF]
reactivity :
Human, Mouse, Rat
purity :
Immobilized antigen affinity chromatography
form :
Affinity purified Immunoglobulins
concentration :
0.75 mg/mL IgG in antibody stabilization buffer
storage stability :
Store at -20°C for long term storage.
tested application :
ELISA (EIA), Immunoprecipitation (IP), Western Blot (WB)
app notes :
ELISA: 1: 50,000. IP: 1: 200. WB: 1: 2,500-1: 5,000
other info1 :
Immunogen: Synththetic peptide corresponding to full length Sarcoplasmic/endoplasmic reticulum calcium ATPase regulator DWORF protein. Conjugation: Unconjugated
other info2 :
Molecular Function: Sarcoplasmic reticulum membrane; Single-pass membrane protein
products categories :
Primary Antibodies; Signal Transduction; Calcium Binding; DWORF Antibody
products description :
Enhances the activity of ATP2A1/SERCA1 ATPase in sarcoplasmic reticulum by displacing ATP2A1/SERCA1 inhibitors, thereby acting as a key regulator of skeletal muscle activity. Does not directly stimulates SERCA pump activity. Enhances sarcoplasmic reticulum Ca2+ uptake and myocyte contractility by displacing the SERCA inhibitory peptides sarcolipin (SLN), phospholamban (PLN) and myoregulin (MRLN).
uniprot summary :
Enhances the activity of ATP2A1/SERCA1 ATPase in sarcoplasmic reticulum by displacing ATP2A1/SERCA1 inhibitors, thereby acting as a key regulator of skeletal muscle activity. Does not directly stimulate SERCA pump activity. Enhances sarcoplasmic reticulum Ca2+ uptake and myocyte contractility by displacing the SERCA inhibitory peptides sarcolipin (SLN), phospholamban (PLN) and myoregulin (MRLN).